The estimated Net Worth of Fredric N Eshelman is at least $9.38 Milione dollars as of 29 January 2018. Fredric Eshelman owns over 335,000 units of G1 Therapeutics Inc stock worth over $9,079,542 and over the last 9 years he sold GTHX stock worth over $0. In addition, he makes $296,673 as Independent Director at G1 Therapeutics Inc.
Fredric has made over 6 trades of the G1 Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 335,000 units of GTHX stock worth $3,350,000 on 29 January 2018.
The largest trade he's ever made was buying 621,720 units of G1 Therapeutics Inc stock on 6 December 2016 worth over $20,995,484. On average, Fredric trades about 91,215 units every 29 days since 2015. As of 29 January 2018 he still owns at least 1,273,428 units of G1 Therapeutics Inc stock.
You can see the complete history of Fredric Eshelman stock trades at the bottom of the page.
Dr. Fredric (Fred) N. Eshelman serves as Independent Director of the Company. Dr. Eshelman founded Eshelman Ventures, LLC in March 2014, which invests in a variety of companies, primarily in the healthcare sector, and has served as a principal since its founding. Dr. Eshelman served as Chief Executive Officer for Pharmaceutical Product Development, Inc., a contract research organization, from June 1990 to December 2011, as Senior Vice President, Development and a member of the board of directors of the former Glaxo Inc., a pharmaceutical company, from 1989 to 1990. He currently serves as chairman of the board of Eyenovia, Inc. a publicly traded biopharmaceutical company, where he has been a member of the board of directors since December 2014. In April 2020, Dr. Eshelman was appointed to the board of directors and became chairman of the board of Aravive, Inc. a publicly traded biotechnology company. Previously, Dr. Eshelman served as the chairman of the board of directors of The Medicines Company, a publicly traded biopharmaceutical company. He has served on the board of directors of Valeant Pharmaceuticals International, Inc. (now known as Bausch Health), a publicly traded Canadian pharmaceutical company, since March 2016. Dr. Eshelman previously served on the board of directors of Furiex Pharmaceuticals, a publicly traded biopharmaceutical company, from 2010 until July 2014, when it was sold to Forest Labs/Actavis, and of Pharmaceutical Product Development, Inc., a contract research organization that was publicly traded until 2011, from 1986 until 2011. He also serves on the boards of directors of a number of privately held biopharmaceutical companies. Dr. Eshelman also served on the executive committee of the Medical Foundation of North Carolina, the board of the North Carolina Biotechnology Center, and the Board of Trustees for the University of North Carolina System. In addition, Dr. Eshelman serves as an adjunct professor at the University of North Carolina at Chapel Hill School of Pharmacy, where he chairs
As the Independent Director of G1 Therapeutics Inc, the total compensation of Fredric Eshelman at G1 Therapeutics Inc is $296,673. There are 17 executives at G1 Therapeutics Inc getting paid more, with Mark Avagliano having the highest compensation of $5,478,390.
Fredric Eshelman is 72, he's been the Independent Director of G1 Therapeutics Inc since 2015. There are no older and 26 younger executives at G1 Therapeutics Inc.
Fredric's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.
Over the last 7 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman e Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
G1 Therapeutics Inc executives and other stock owners filed with the SEC include: